Antonio Ahn is a medical researcher from New Zealand. He received his PhD in pathology from the University of Otago, where he currently works as a lab demonstrator. His research focuses on bioinformatics analysis of RNA-seq and methylation data to study protein-coding genes, lncRNAs, transposable elements, and immune cell infiltration in cancer. He has published several papers on epigenetic changes and drug resistance in melanoma.

1. Curriculum Vitae
Antonio Ahn
Dunedin,
New Zealand
E-mail: Antonio.Ahn@otago.ac.nz
Citizenship: New Zealand
Blog: https://antonioahn.github.io/
GitHub: https://github.com/AntonioAhn
Education
Doctor of Philosophy (PhD)
University of Otago
Masters in Medical Laboratory Science
Graduated with Distinction, University of Otago
Postgraduate Diploma in Medical Laboratory Science
Graduated with Distinction, University of Otago
2015- Present
2014
2011
Bachelor of Medical Laboratory Science
University of Otago
2007-2010
Research experience
PhD, Pathology Department, Otago University
Bioinformatics: RNA-sequencing (protein-coding genes, lncRNA and
Transposable Elements using SalmonTE). Microarray gene expression
(Affymetrix, Agilent Illumina platforms). Immune decomposition tools
(CiberSort, xCell, MCPcounter, TIMER). Methylation 450k, TCGA data
analysis (RNA-seq, methylation 450k)
Wet-lab: Flow Cytometry, Cell culture, siRNA knockdown, Sequenome
(DNA methylation), PCR (RT-qPCR, sanger sequencing, nested PCR),
phenotypic assays: migration (scratch assay, Bowden chamber), proliferation
(MTT assay), live cell imaging (Incucyte).
2015- Present
Employment
Lab Demonstrator for undergraduate papers, Pathology Department.
University of Otago
Exam Supervisor, Disability Information and Support centre.
University of Otago
Medical Laboratory Scientist. Department of immunology and infectious
diseases. Dunedin hospital. Part-time work (20 hours per week)
2015- Present
2016 – Present
2012- 2016

2. Publications
q Chatterjee A, Rodger EJ, Ahn A, Stockwell PA, Parry M, Motwani J, et al. Marked Global DNA
Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma. iScience.
2018;4:312-25.
q Chatterjee A, Ahn A, Rodger EJ, Stockwell PA, Eccles MR. A Guide for Designing and Analyzing
RNA-Seq Data. Methods Mol Biol. 2018;1783:35-80.
q Ahn, A., Chatterjee, A., & Eccles, M. R. (2017). The Slow Cycling Phenotype: A Growing Problem
for Treatment Resistance in Melanoma. Mol Cancer Ther, 16(6), 1002-1009
q Chatterjee A, Macaulay EC, Ahn A, Ludgate JL, Stockwell PA, Weeks RJ, et al. Comparative
assessment of DNA methylation patterns between reduced representation bisulfite sequencing and
Sequenom EpiTyper methylation analysis. Epigenomics. 2017;9(6):823-32.
q Chatterjee, A., Stockwell, P.A., Ahn, A., Rodger, E.J., Leichter, A.L., and Eccles, M.R. (2016).
Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common
DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma
metastasis. Oncotarget.
q Jones, A.M., Ferguson, P., Gardner, J., Rooker, S., Sutton, T., Ahn, A., Chatterjee, A., Bickley, V.M.,
Sarwar, M., Emanuel, P., Kenwright, D., Shepherd, P.R., and Eccles, M.R. (2016). NRAS and
EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South
Island of New Zealand. Oncotarget 7, 41017-41030.
q Royds, J. A., Pilbrow, A. P., Ahn, A., Morrin, H. R., Frampton, C., Russell, I. A., . .Slatter, T. L.
(2015). The rs11515 Polymorphism Is More Frequent and Associated With Aggressive Breast
Tumors with Increased ANRIL and Decreased p16 (INK4a) Expression. Front Oncol, 5, 306. doi:
10.3389/fonc.2015.00306
q Ahn, A., and Eccles, M.R. (2013). Targeted therapy; from advanced melanoma to the adjuvant
setting. Front Oncol 3, 205.
q Eccles, M.R., He, S., Ahn, A., Slobbe, L.J., Jeffs, A.R., Yoon, H.S., and Baguley, B.C. (2013). MITF
and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a "Genetic Switch" Theory
Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma. Front Oncol 3,
229.
q Royds, J.A., Al Nadaf, S., Wiles, A.K., Chen, Y.J., Ahn, A., Shaw, A., Bowie, S., Lam, F., Baguley,
B.C., Braithwaite, A.W., Macfarlane, M.R., Hung, N.A., and Slatter, T.L. (2011). The CDKN2A
G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism
tumors and is associated with poorer survival. PLoS One 6, e26737.
Awards
q Poster Prize, 2018. QMB Cancer conference, Queenstown, New Zealand
q Poster Prize, 2018. Epigenetics User Group Symposium, Dunedin, New Zealand
q Poster Prize, 2018. Dunedin School of Medicine Research Symposium, Dunedin, New
Zealand.
q Speaker Prize, 2017. QMB Genome biology conference, Queenstown, New Zealand.
q Poster Prize, 2017. Pathology poster symposium, Dunedin, New Zealand.
Presentations
q Epigenetics User Group Symposium, Dunedin, New Zealand, 2018
q South Island Seminar. Medical laboratory science 2018
q QMB Genome Biology conference 2017
q South Island Seminar. Medical laboratory science. 2016